Whether pediatric studies are necessary or waivable

Situation

A company with a CMC site change mid-review cannot treat an inspector asking for batch records you cannot produce this week as color commentary on complete-response-letter deficiency list. Clinical-development physician must close pediatric studies are necessary from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled FDA Response and Labeling process in a company with a CMC site change mid-review, given complete-response-letter deficiency list.
• An inspector asking for batch records you cannot produce this week is the event in complete-response-letter deficiency list that forces Pediatric studies are necessary for clinical-development physician under Pharma & Life Sciences.
• Complete-response-letter deficiency list shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a FDA Response and Labeling program failure.
• Complete-response-letter deficiency list cannot decide pediatric studies are necessary yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move pediatric studies are necessary for clinical-development physician.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for clinical-development physician in a company with a CMC site change mid-review.